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approach for progressive non-pontine pediatric
high-grade gliomas: preliminary experiences from
the German HIT-HGG study group
Klaus Müller1†, Heike Scheithauer2†, Sophie Pietschmann1, Marion Hoffmann3, Jochen Rössler4, Norbert Graf5,
Brigitta G Baumert6, Hans Christiansen7, Rolf-Dieter Kortmann1, Christof M Kramm3 and André O von Bueren3*Abstract
Background and purpose: The aim of the present analysis was to assess the feasibility, toxicity, and the tumor
control of reirradiation as a salvage treatment for progressive pediatric non-pontine high-grade gliomas (HGG).
Patients and methods: The database of the Reference Center for Radiation Oncology of the German HIT
(HIT = German acronym for brain tumor) treatment network for childhood brain tumors was screened for children
who were reirradiated for progressive non-pontine HGG.
Results: We identified eight patients (WHO grade III: n = 5; WHO grade IV: n = 3) who underwent reirradiation
between April 2006 and July 2012. Median age was 13.5 years at primary diagnosis and 14.8 years at first
progression. All patients initially underwent surgery (incomplete resection, n = 7; biopsy, n = 1) followed by
radiochemotherapy. Relapses occurred inside (n = 2), at the margin (n = 4), and outside of the preirradiated area
(n = 2). In all patients, reirradiation was tolerated well without significant acute toxicity. Temporary clinical
improvement and tumor regression on magnetic resonance imaging (MRI) following reirradiation was reported
(n = 3). However, all patients finally died by disease progression. Median survival time was 26.2 months from initial
diagnosis and 11.4 months after first progression. Median time interval between initial radiotherapy and first
reirradiation was 9.0 months. In six patients, all macroscopic tumor deposits were reirradiated. In these patients,
median progression-free (overall) survival from the start of reirradiation was 2.4 (4.6) months.
Conclusion: Our analysis, although based on a limited patient number, suggests that reirradiation of progressive
non-pontine HGG is feasible in children. Benefit in terms of quality of life and/or survival needs to be assessed in a
prospective and ideally in a randomized manner.
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Until present, prognosis of progressive high-grade gli-
omas (HGG) has remained dismal. Based on numerous
retrospective studies reporting on encouraging survival
rates and favorable toxicity profile, reirradiation has been
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unless otherwise stated.patients with relapsed HGG [1-3]. However, as tumor and
molecular biology differs between adult and pediatric
HGG and as the juvenile brain is particularly vulnerable to
radiation-induced injury, results from the above men-
tioned studies cannot be extrapolated to children [4]. In
this analysis we specifically address the feasibility, out-
come, and radiation-induced toxicity in a small cohort of
pediatric patients with progressive non-pontine HGG who
underwent a salvage treatment containing a second course
of radiation therapy.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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The database of the Reference Center for Radiation On-
cology of the German HIT (HIT = German acronym for
brain tumor) treatment network for childhood brain tu-
mors was screened, between 2006–2012, for children
who underwent a second course of radiation therapy for
progressive non-pontine HGG. Clinical information was
extracted from patient medical charts. The date of initial
diagnosis was defined as the date of the first tumor re-
section or biopsy. The date of progression was deter-
mined by neuroradiological imaging. Progression-free
(PFS) and overall survival (OS) were assessed using the
Kaplan–Meier method. All statistical analyses were per-
formed with SPSS, version 20 (SPSS Inc., Chicago, IL,
USA). General informed consent had been given for data
acquisition and analyses in the context of the corre-
sponding clinical trials of the first-line treatment.
Results
We identified eight pediatric HGG patients (male, n = 5)
who underwent a second course of radiation therapy bet-
ween April 2006 and July 2012. Median age was 13.5 years
(range, 10.3 – 16.7 years) at initial diagnosis and 14.8 years
(range, 11.0 - 17.5 years) at first progression after initial
treatment.
First-line treatment
Surgery included incomplete resection (n = 7), or bi-
opsy (#6). All patients were treated by adjuvant ra-
diochemotherapy (median total dose 59.4 Gy, range,
54.0 Gy – 60.0 Gy) according to the German HIT-GBM D
(EU-205100, NCT00278278) (n = 4) or HIT-HGG 2007
(EudraCT 2007-000128-42; ISRCTN19852453) (n = 4)Table 1 Patients characteristics I, first-line treatment and tim
Patient Age at initial Dx
(years)/gender
Tumor location Pathology First-line treat
1 11/M temporo-parietal AA pSx → RCT →
2 15/M central AA/GBM* pSx → MTX →
second surgery
3 10/F frontal AOD pSx → RCT →
4 13/F parietal + insular GBM pSx → RCT →
5 13/M frontal GBM pSx → RCT →
6 14/M hemispheric AA Bx→CT (carbop
etoposide, VCR)
7 10/M temporal GBM pSx → RCT →P
8 16/F thalamic AA pSx → RCT →m
Dx: diagnosis, M: male, F: female, AA: anaplastic astrocytoma (WHO grade III), AOD:
(WHO grade IV), Bx: biopsy, pSx: partial surgery, RT: radiation therapy, RCT: radioche
CCNU: lomustine, PEV: cisplatin, vincristine, CCNU, VCR: vincristine, VBL: vinblastine,
→: followinged by the next treatment.
*AA at initial diagnosis, GBM at first recurrence.protocols. One patient (#2) received methotrexate (MTX)
prior to radiochemotherapy (according to the HIT-GBM
D protocol, arm M), and second look surgery of the irradi-
ated tumor was performed. Another patient (#6) received
chemotherapy consisting of carboplatin, etoposide and
vincristine (VCR) prior to radiochemotherapy as a supra-
tentorial primitive neuroectodermal tumor (CNS-PNET)
had been initially suspected before central review con-
firmed a HGG. All patients received maintenance chemo-
therapy consisting of temozolomide (TMZ) (n = 5) or
lomustine (CCNU), VCR and steroids (n = 3) (Table 1).
Histology
Histological assessment initially revealed five WHO grade
III (anaplastic oligodendroglioma (AOD) n = 1, anaplastic
astrocytoma (AA) n = 4) and three WHO grade IV tumors
(glioblastoma multiforme (GBM)). In addition, the tumor
tissue from one patient with an AA (#2) showed at the
time of the first relapse histopathological features fulfilling
the diagnostic criteria of a GBM (AA → GBM). All cases
were centrally reviewed (German Brain Tumor Reference
Center, Bonn, Germany).
Second-line treatment
Salvage treatment after first relapse differed considerably
between the eight patients.
Patient #1 (AA) relapsed at the margin of the preir-
radiated area 9.5 months after surgery. Subsequently,
he received stereotactic hypofractionated reirradiation
(single doses of 4 × 5 Gy and 1 × 4.2 Gy) to a total dose
of 24.2 Gy and concurrent TMZ. Prior exposition to
radiotherapy in the reirradiated area was approximately
24 Gy. Salvage treatment was tolerated well withoute to first progression









mCT 54.0/27/ PEV/VCR/PEIV TMZ 9.5
RCT →
→ mCT
59.4/33/ PEV/VCR/PEIV CCNU/VCR (VBL) 17.4
mCT 59.4/33/ PEV/VCR/PEIV CCNU/VCR/
prednisolone
9.4
mCT 60/30/TMZ TMZ 5.0
mCT 59.4/33/ TMZ TMZ 49.9
latin,




D → mCT 59.4/33/ TMZ TMZ 2.5
CT 59.4/33/ TMZ TMZ 9.0
anaplastic oligodendroglioma (WHO grade III), GBM: glioblastoma multiforme
motherapy, mCT: maintenance chemotherapy, TMZ: temozolomide,
PEIV: cisplatin, vincristine, CCNU, ifosfamide, PD: progressive disease.
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cycles of PCV chemotherapy consisting of procarbazine,
CCNU and VCR were administered. Three months after
the start of reirradiation, a deterioration of the patient’s
general condition was observed. A cranial MRI showed
clear evidence for a progressive disease. The patient died
4.9 months after the relapse.
Patient #2 (AA) relapsed at the margin of the preirra-
diated area 17.4 months after surgery. Prior radiation ex-
posure was approximately 30 Gy. An incomplete tumor
resection was performed. Interestingly, whereas the his-
topathological assessment of the initial tumor revealed
an AA, the tissue of the relapsed tumor showed clear
evidence for a GBM. Subsequently, a treatment with
TMZ (orally) and intraventricular MTX was adminis-
trated. Approximately 13 months after the relapse tumor
resection cranial MRI demonstrated again a progressive
disease. A reirradiation (single dose 1.8 Gy, total dose
55.8 Gy) with concurrent TMZ was performed. Apart
from a focal alopecia and moderate erythema no acute
radiation-induced adverse reactions or toxicities were re-
ported. Hematotoxicity was mild. Of note, the boy was
able to attend the school during the treatment. Following
re-radiochemotherapy high-dose TMZ was administered.
Regrettably, the child did experience disease progression
only 2.4 months after the start of reirradiation. Despite a
further salvage treatment attempt with nimotuzumab, the
patient died of disease progression 20.5 months after the
first recurrence.
Patient #3 (AOD) relapsed at the margin of the preir-
radiated area 9.4 months after the surgery. Following
partial resection, the girl received reirradiation with 6 ×
5 Gy without any complications. Then, the girl received
dendritic cell vaccination, 1.6 months after start of the
reirradiation, the cranial MRI again revealed disease pro-
gression. The child finally died due to tumor progression
5.3 months after the first relapse.
Patient #4 (GBM) recurred at the margin of the radi-
ation field 5.0 months after the initial surgery. Salvage
treatment consisted of reirradiation (17 × 1.8 Gy) with
concurrent TMZ, and this treatment was tolerated well.
Subsequently, the girl received metronomic chemotherapy
with the COMBAT regimen [5]. The tumor responded
and the neurological status of the patient significantly im-
proved. Unfortunately, 35.9 months after the start of reir-
radiation the patient experienced a multilocular second
relapse. The girl died 39.5 months after the first relapse
despite the girl was treated with a salvage chemotherapy
consisting of CCNU and trofosfamide.
Patient #5 (GBM) experienced a relapse within the
preirradiated area 49.9 months after primary surgery.
The salvage chemotherapy with TMZ was initiated and
this resulted initially in a tumor regression. Due to a
second tumor progression the patient finally receivedreirradiation with 17 × 1.8 Gy. This treatment was toler-
ated remarkably well, despite a relatively large radiation
field due to the large tumor volume of 125 cm3. More-
over, the patient received bevacizumab every second
weeks. Four weeks after the end of the reirradiation, a
cranial MRI showed a very good partial response of the
relapsed tumor (Figure 1). At the same time, the neu-
rological status of the boy improved. Unfortunately,
2.9 months after the start of reirradiation, the patient
experienced a multilocular tumor progression within
and outside of the reirradiated area. Despite an inten-
sification of the ongoing bevacizumab treatment by
addition of irinotecan, the patient died 11.5 months
after the first relapse.
Patient #6 (AA) had a multilocular relapse outside of
the preirradiated volume 12.2 months after initial sur-
gery. With a palliative objective, he received reirradiation
focused on a symptomatic tumor deposit in the left ce-
rebellar peduncle (25 × 1.8 Gy). Metronomic TMZ was
administered simultaneously. Treatment was effective.
Neurological status, especially the gait pattern, signifi-
cantly improved. Six weeks after the end of irradiation,
cranial MRI demonstrated a tumor regression within and
progressive disease outside of the reirradiated area. There
were no radiation-induced side effects reported requiring
any supportive treatment. Approximately two months
later, the boy received radiation therapy for the third time.
The radiation therapy was directed at a tumor deposit in
the area of the right lateral ventricle (17 × 1.8 Gy). The
treatment was well tolerated. Two months after the end of
the third irradiation, the MRI again showed disseminated
tumor progression, however not in the preirradiated areas.
Subsequently, high-dose TMZ (5 days on/5 days off) was
started. Finally, a fourth course of stereotactic radiation
therapy to a tumor deposit in the right cerebellopontine
angle (3 × 5 Gy) was given without any acute side effects.
The patient finally died 11.3 months after the first relapse.
Patient #7 (GBM) relapsed locally 2.5 months after
the initial surgery. The relapsed tumor was incompletely
resected. The boy received dendritic cell vaccination [6].
The patient finally experienced a multilocular relapse
with leptomeningeal spread along the entire craniospinal
axis. He subsequently underwent palliative craniospinal
irradiation with 10 × 3 Gy with concurrent TMZ. Never-
theless, the disease progressed and the boy finally died
10.6 months after the first relapse.
Patient #8 (AA) experienced a local relapse, 9.0
months after the initial surgery. The relapsed tumor pro-
gressed slowly. In the further course of the disease, a
cerebellar metastasis with brain stem infiltration oc-
curred. This tumor manifestation was subsequently ir-
radiated with conventionally fractionated reirradiation to
a total dose of 54 Gy. There were no supportive treat-
ments requiring radiation-induced side effects. Shortly
Figure 1 Patient 5: Contrast enhanced T1 weighted MRI, coronal plane, a) before, b) four weeks after reirradiation: partial remission of
the relapsed tumor four weeks after a second course of radiation therapy with 17 × 1.8 Gy = 30.6 Gy.
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sion and refused further treatment. She finally died 9.2
months after the beginning of reirradiation and 20 months
after first relapse (Table 2).Survival
The median survival time from initial diagnosis was
26.2 months (range, 13.1 – 61.4 months) (Figure 2) and
11.4 months (range, 4.9 – 39.5 months) from the time of
the first recurrence. Median time interval between the
end of the initial radiotherapy and the beginning of the
reirradiation was 9.0 months (range, 3.8 – 52.1 months).
The tumor control of the six patients, who received reir-
radiation of all visible tumor lesions was moderate with
a median progression-free (overall) survival after the start
of reirradiation of 2.4 ± 0.8 months (4.6 ± 1.4 months)
(Figure 3).Discussion
General aspects
In the present analysis, we retrospectively assessed eight
pediatric patients with non-pontine HGG who under-
went reirradiation as part of their salvage treatment after
disease progression. Our series is small, however, to the
best of our knowledge, this is the first report on reirra-
diated pediatric non-pontine HGG.Surprisingly, the idea of reirradiating progressive child-
hood HGG dates back to the 1980ies. In the Children’s
Cancer Group (CCG) study 943, patients who showed
tumor recurrences 12 months after the diagnosis could
optionally receive irradiation to the recurrent tumor
sites up to a dose of 3000 rad in 15–18 fractions. How-
ever, in none of the 43 relapsed patients the possibility
of reirradiation was exhausted [7]. Apparently, pediatric
radiation oncologists have been reluctant to reirradiate
relapsed or progressive HGG due to their increased vul-
nerability of the CNS to radiation therapy. Hence, the
fear of an unacceptably high incidence of neurological
and other radiotherapy-induced toxicity and sequelae
may have limited the use of a second course of radiation
therapy. Moreover, even in adult patients, the benefit of
reirradiation in terms of survival is still an issue of de-
bate. To assess the impact of reirradiation in adult recur-
rent GBM patients, the Radiation Therapy Oncology
Group (RTOG) 1205 randomized phase II trial is cur-
rently validating the survival benefit of reirradiation in a
prospective randomized setting.Feasibility and safety of reirradiation in children
In our small series, we report on children receiving a
second course of radiation therapy. In four cases (pa-
tients #1 – #4) the target volumes for reirradiation were
located at the margins of and in two cases (patients #5
Table 2 Patients characteristics II, salvage treatment, time from first to second progression and time from initial diagnosis to death
Patient Location of first
relapse





of second RT to
progression (months)
Time from start





1 margin of RT 1 field sRCT → PCV → PD → death 24.2/5/ TMZ 3.2 4.6 4.9
2 margin of RT 1 field pSx (GBM) → CT (MTX + TMZ) → second relapse → RCT 2 → mCT (TMZ) →
PD → nimotuzumab → PD → death
55.8/31/TMZ 2.4 6.1 20.5
3 margin of RT 1 field pSx → RT 2 → PD → dendritic cell vaccination → PD → dendritic cell
vaccination + TMZ → PD → death
30/6 1.6 3.8 5.3
4 margin of RT 1 field RCT 2 → COMBAT chemotherapy → multilocular recurrence → lomustine,
trofosfamide → death
30.6/17/TMZ 35.9 38.3 39.5
5 within RT 1 field TMZ → PD → RT 2 → 30.6/17 → bevacizumab → multilocular recurrence →
irinotecan + bevacizumab → death
30.6/17 2.9 6.7 11.5
6 multilocular, outside RT
1 field
RCT 2 (cerebellar peduncle) → mCT (TMZ) → RT 3 (30,6 Gy, lateral ventricle) →
PD → TMZ → multilocular progress → TMZ + RT 4 (3 × 5 Gy, cerebellopontine




7 within RT 1 field pSx → dendritic cell vaccination → extensive dissemination → RCT 2 (CSI +
TMZ) → PD death
30/10 /TMZ 1.4 3.9 10.6
8 outside RT 1 field watch and wait →local PD and metastasis to cerebellum → RT (cerebellum) →




RT: radiation therapy, RCT: radiochemotherapy, sRCT: stereotactic radiotherapy + concurrent chemotherapy, PCV: procarbazine, lomustine, vincristine, PD: progressive disease, TMZ: temozolomide, pSx: partial surgery,
GBM: glioblastoma multiforme (WHO grade IV), CT: chemotherapy, MTX: methotrexate, mCT: maintenance chemotherapy, COMBAT: Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment (including
low-dose daily temozolomide, etoposide, celecoxib, vitamin D, fenofibrate and retinoic acid), CSI: craniospinal irradiation. →: followed by the next treatment.

















Figure 2 Progression-free and overall survival after initial
diagnosis of 8 children with high-grade gliomas, who underwent
a second course of radiotherapy after tumor progression.
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significant ionizing preloads to the surrounding normal
brain tissue ranging between 25 Gy (see patients #1
and #2) and almost 60 Gy had to be expected. Moreover,
at least in patient #4, the time interval between the end of
initial and the beginning of the reirradiation was rather
short (3.8 months). Most experts in the field suggest a
radiation-free interval of at least six months between the
first and second irradiation [8-10]. However, our very lim-
ited experience might provide evidence that some patients
may tolerate reirradiation within a shorter (<6 months)
radiation-free interval.Figure 3 Progression-free and overall survival after the start of
reirradiation of the six children, in whom the planned target
volume of reirradiation contained all macroscopic
tumor deposits.The reirradiation was tolerated remarkably well in
our small cohort. Alopecia and reddening of the skin
were reported. No major unexpected toxicities, and no
treatment-related deaths were reported. Moreover, no
reirradiation-induced necrosis which would have required
treatment did occur in any patient during the further
course of the disease. This is in accordance with the con-
clusions of two important reviews on normal brain tissue
tolerance which stated that radiation-induced necrosis has
to be expected only at cumulative normalized total doses
(single dose, 2 Gy; α/β, 3 Gy) > 102 Gy and just 1–2 years
after irradiation, i.e. after the expected survival time in
progressive HGG patients [11,12].
Tumor response following reirradiation
In three of our patients, temporary but significant im-
provement of the neurological status and regression of the
(re-) irradiated tumor deposits were reported (patient #4,
#5, and #6). These findings are in agreement with the
experiences reported by Fontanilla and colleagues. They
published a series of five children with diffuse intrinsic
pontine gliomas whose disease progressed after initial ra-
diochemotherapy and subsequent salvage chemotherapy.
A second course of radiotherapy was given with concur-
rent chemotherapy up to a dose of 20 Gy or 18 Gy. Four
patients had substantial clinical improvement of their
symptoms (improvement in speech, ataxia, and swallow-
ing). Three patients showed an improved mobility after
reirradiation. Four patients had decreased tumor size
on posttreatment MRI. Acute radiation-related toxicities
were fatigue (n = 2), alopecia (n = 2), and reduced appetite
(n = 1). No grade 3 or 4 toxicities were reported [13].
Impact of reirradiation on survial
Regrettably, in our small series, reirradiation did not
demonstrate convincing efficacy in terms of long-term
tumor control and survival. In six patients the target vol-
ume of reirradiation contained all macroscopic tumor
deposits. Only one of these patients (patient #4) showed
sustained stable disease for 35.9 months after reirra-
diation. Surprisingly, the histology of the tumor was a
GBM, and the child had progressed only five months
after initial diagnosis despite intense first-line treatment
consisting of surgery, followed by adjuvant radiochemo-
therapy (TMZ) and TMZ maintenance chemotherapy.
The other five patients did progress less than 3.5 months
after the start of reirradiation. Median progression-free
(overall) survival from the start of reirradiation was
2.4 ± 0.8 months (4.6 ± 1.4 months) and hence by far
less than hoped on the basis of prior experiences gained in
adults who had undergone a second course of radiation
therapy for refractory HGG. Scholtyssek et al. recently
reported a median progression-free (overall) survival of
4.3 (7.7) months in a cohort of 64 adult HGG patients
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been treated at progression using a second series of radio-
therapy with or without concurrent/subsequent chemo-
therapy [14]. Other authors even reported much more
favorable outcomes with median overall survivals ranging
between 9.5 and 11 months [15-17]. Of note, the impact of
reirradiation on survival appears to be difficult to interpret
in our series as we report on a limited number of patients
with differing primary treatment and heterogeneous sal-
vage therapy approaches. In addition, three of our patients
(patients #2, #5 and #7) received a second course of radi-
ation therapy at the time of the second relapse thereby in-
fluencing the survival data of the present study (Table 2).
Conclusions
In summary, our findings, although based on a limited
patient number, suggest that reirradiation might be feas-
ible in progressive pediatric non-pontine HGG. The rec-
ommended radiation dose depends on the location of
the relapse, the age of the patients, and the ionizing pre-
loads of the relapse area. Further evaluation of such ca-
ses is necessary in order to better delineate feasibility,
toxicity, and impact on outcome of this new treatment
approach in pediatric non-pontine HGG patients with
relapsed tumors.
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